Bon Secours Mercy Health, Greenville, South Carolina.
University of Virginia Medical School, Charlottesville, Virginia.
J Urol. 2023 Jun;209(6):1082-1090. doi: 10.1097/JU.0000000000003452. Epub 2023 Apr 25.
In 2022 the American Urological Association (AUA) requested an Update Literature Review (ULR) to incorporate new evidence generated since the 2020 publication of this guideline. The resulting 2023 Guideline Amendment addresses updated recommendations for patients with advanced prostate cancer.
The ULR addressed 23 of the original 38 guideline statements and included an abstract-level review of eligible studies published since the 2020 systematic review. Sixteen studies were selected for full text review. The current summary presents the updates made to the Guideline as a result of that new literature.
The Advanced Prostate Cancer Panel amended evidence- and consensus-based statements based on an updated review to aid clinicians in the management of patients with advanced prostate cancer. These statements are detailed herein.
This Guideline Amendment provides a framework designed to improve a clinician's ability to treat patients diagnosed with advanced prostate cancer with the most current evidence-based information. Further research and publication of high-quality clinical trials will be essential to continue to improve the quality of care for these patients.
2022 年，美国泌尿外科学会（AUA）要求进行更新文献综述（ULR），以纳入自本指南 2020 年发表以来产生的新证据。由此产生的 2023 年指南修正案针对晚期前列腺癌患者的更新建议。
ULR 针对最初的 38 条指南陈述中的 23 条进行了处理，并对自 2020 年系统评价以来发表的符合条件的研究进行了摘要水平的审查。选择了 16 项研究进行全文审查。目前的摘要介绍了由于新文献而对指南进行的更新。
高级前列腺癌小组根据更新的审查对基于证据和共识的陈述进行了修订，以帮助临床医生管理晚期前列腺癌患者。这些陈述在此详细介绍。
本指南修正案提供了一个框架，旨在提高临床医生根据最新循证信息治疗诊断为晚期前列腺癌患者的能力。进一步的研究和高质量临床试验的发表对于继续提高这些患者的护理质量至关重要。
Zotero 插件